Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011854 (type 1 diabetes)
 20,749 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Several haemostatic abnormalities are associated with proliferative diabetic retinopathy. While abnormalities in plasma fibrinolytic activity have been described in diabetic retinopathy, platelets (a rich source of plasminogen activator inhibitor type 1, PAI-1) have received little attention. As a result, little is known about the fibrinolytic potential of circulating whole blood in diabetic retinopathy. The concentrations of tissue-type plasminogen activator (t-PA) and of its fast-acting inhibitor. PAI-1 were measured in plasma from eight patients with type 1 diabetes complicated by proliferative retinopathy, and from eight patients with type 1 diabetes and background or no retinopathy, matched for age, sex and duration of diabetes. The concentration of PAI-1 in platelets was also measured. The ratio of t-PTA to PAI-1 in plasma was significantly higher in patients with proliferative retinopathy than in those without (0.66 vs. 0.37, p < 0.02). The average quantity of PAI-1 per platelet was significantly lower in the group with proliferative retinopathy (0.33 vs. 0.50 ng/10(6) platelets, p < 0.02). These data suggest that among patients with type 1 diabetes, total circulating fibrinolytic potential is higher in those with proliferative retinopathy.
 ...
PMID:Circulating tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in proliferative diabetic retinopathy: a pilot study. 1066 20

Pancreas transplantation is the only treatment for type I diabetes mellitus that can induce an insulin-independent normoglycemic state. Because of the need for immunosuppression, it has been most widely applied in uremic diabetic recipients of kidney transplant with a high success rate, particularly when done as a simultaneous (SPK) procedure (insulin independence > 80% at 1 year) with patient and kidney graft survival rates equivalent to or higher than in those who receive a kidney transplant alone. The results of solitary pancreas transplants (PAK in nephropathic diabetic recipients or PTA in nonuremic recipients) have also dramatically improved; 1-year graft survival rates are more than 80% and 70%, respectively, with the new immunosuppressants tacrolimus and mycophenolate mofetil. Multiple factors are important for successful application of pancreas transplantation, as summarized in this review.
 ...
PMID:Pancreas transplantation for treatment of diabetes mellitus. 1134 3

Transplantation of pancreas is a generally accepted treatment option for patients with type 1 diabetes mellitus. This procedure restores physiological insulin secretion, resulting in long-term normoglycemia and preventing complications of diabetes. One of the therapeutic possibilities is pancreas after kidney transplantation (PAK) for patients with previous successful kidney transplantation. There is evidence that patient and kidney graft survival is higher in PAK compared with diabetic recipients of kidney or pancreas alone (PTA). We report a case of pancreas after kidney transplantation in a 38 year-old male with type 1 diabetes mellitus of 21 year duration. One year before PAK he received cadaveric kidney transplant. Pancreatic graft was placed on the left side of the pelvis and enteric drainage was used. Immunosuppression consisted of antithymocyte globulin (ATG), daclizumab, tacrolimus, mycophenolate mofetil, and steroids. Ten months after surgery the patient stays normoglycemic, insulin-independent with good kidney function (Cr-1,5 mg/dl).
 ...
PMID:Pancreas after kidney (PAK) transplantation--first case in Poland. 1703 94